Clinical trials
Chronic Spontaneous Urticaria clinical trials
Below are recruiting chronic spontaneous urticaria clinical trials, each written for real people, not researchers. We’re tracking 26 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07256392Enrolling by invitationPhase 3
Long-term safety of barzolvolimab for chronic hives
This study is a long-term extension of the barzolvolimab trial for people with chronic spontaneous urticaria (CSU). It tests the continued safety and effectiveness of barzolvolimab over a longer period for those who have already completed the initial phase 3 study.
Birmingham, AlabamaAges 18 years+ - NCT06865651RecruitingPhase 2
Study of Remibrutinib for chronic hives not helped by antihistamines
This trial tests an experimental drug called Remibrutinib for people with chronic hives (urticaria) that are not well controlled with standard antihistamines. The goal is to see if the drug reduces symptoms like itching and wheals.
North Miami Beach, FloridaAges 18 years+ - NCT06868212RecruitingPhase 3
Testing remibrutinib vs dupilumab for chronic hives
This study compares two oral medications, remibrutinib and dupilumab, to see which works faster for chronic hives that don't get better with standard antihistamines. You may be eligible if you have had hives and itching for at least 6 months and they are still active despite daily antihistamines.
Birmingham, AlabamaAges 18 years+ - NCT07765979Recruiting
Diet plans for teenage hives
This study tests two diets — a Mediterranean diet and a low-histamine diet — to see if they help reduce hives in teenagers with chronic spontaneous urticaria. If your child qualifies, they will follow one of these diets for a period and we will monitor their symptoms.
IstanbulAges 12–18 - NCT07632040Enrolling by invitation
Diet changes for chronic hives in teens
This study tests whether avoiding certain foods and food additives can reduce chronic hives (itchy welts on skin) in children and teenagers. Researchers will have participants follow a special diet and track their symptoms over time.
Istanbul, FatihAges 1–18 - NCT06924762RecruitingPhase 2/Phase 3
Low-dose IL-2 for chronic hives that don't respond to usual treatment
This study tests a low-dose immune therapy (interleukin-2) for people with chronic hives that don't get better with standard allergy pills. If you are an adult with ongoing hives and itching despite daily antihistamines, this trial might offer a new treatment option.
Changsha, HunanAges 18–74 - NCT07402213RecruitingPhase 3
Study of JYB1904 for chronic spontaneous urticaria
This trial tests a new injectable medicine (JYB1904) to see if it can reduce itching and hives better than standard antihistamines alone. If you have chronic hives with no clear cause and still get symptoms despite taking antihistamines, this study may be an option for you.
BeijingAges 18 years+ - NCT07717905RecruitingPhase 1/Phase 2
Testing BBT001 for chronic hives
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
Wuhu, AnhuiAges 18–75 - NCT06927999RecruitingPhase 2
Experimental medicine for chronic hives
This trial tests an experimental medicine for chronic hives (called chronic spontaneous urticaria). It is for people whose hives still bother them about once or twice a month despite daily treatment, and who do not have heart problems.
Glenview, IllinoisAges 18–65 - NCT05916937RecruitingPhase 4
Test longer dosing of omalizumab for chronic hives
This Phase 4 study looks at whether extending the time between omalizumab injections can still control chronic spontaneous hives (CSU). It may help some people need fewer injections while keeping symptoms under control.
Copenhagen, Copenhagen NAges 18 years+ - NCT06509334RecruitingPhase 2
Study of JYB1904 for chronic hives
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07166211RecruitingPhase 2
Study of CM512 injection for chronic hives
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07219615RecruitingPhase 2
Study of Ritlecitinib for Chronic Hives Not Helped by Antihistamines
This study is testing an experimental daily pill called ritlecitinib for adults whose chronic hives don’t go away with standard antihistamines. It may be a new option if your hives are active and you are not on omalizumab or are willing to stop it for several months.
Phoenix, ArizonaAges 18 years+ - NCT07378527RecruitingPhase 2/Phase 3
Study of ICP-332 for chronic hives not helped by antihistamines
This trial tests an experimental drug called ICP-332 for people with chronic spontaneous urticaria (long-term hives) that is not well controlled by standard antihistamines. The goal is to see if the drug is safe and effective at reducing hives.
Bengbu, AnhuiAges 18–75 - NCT07408219Recruiting
Study of Remibrutinib for chronic hives
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
East Hanover, New JerseyAges 18–100 - NCT07415551RecruitingPhase 2
New drug for chronic hives that don't respond to allergy pills
This study tests an investigational medication called lesigercept for people with chronic hives that don't get better with standard allergy pills. The goal is to see if it can reduce itching and hives better than placebo.
Sofia, SofiaAges 18–75 - NCT07540910RecruitingPhase 1
Safety study of EDP-978 in healthy adults
This is an early-stage study testing a new experimental drug called EDP-978 in healthy volunteers to see if it is safe and how the body processes it. Researchers will give participants single or multiple doses and monitor for side effects and how the drug moves through the body.
San Antonio, TexasAges 18–65 - NCT07431658Enrolling by invitation
Diet and stress effects on omalizumab response in chronic hives
This study looks at how diet and oxidative stress (a type of cell damage) affect the severity of chronic hives and how well patients respond to the medication omalizumab (Xolair). It may help find ways to improve treatment by understanding these factors.
IstanbulAges 18–65 - NCT07181369RecruitingPhase 1
Study of GTX-B001 for chronic inducible urticaria
This trial tests a new drug, GTX-B001, in healthy people and those with a type of hives called chronic inducible urticaria (specifically cold-induced or scratch-induced hives). The goal is to see if it's safe and helps control symptoms that don't respond well to standard antihistamines.
BerlinAges 18–75 - NCT07686484RecruitingEarly Phase 1
Testing a new drug in healthy volunteers
This trial tests an experimental drug called HRS-3095 in healthy people to check its safety and how the body handles it. It may help find the right dose for future studies.
Bayswater, VictoriaAges 18–55 - NCT07642557Recruiting
Real-world remibrutinib use for chronic hives in Germany
This study observes how remibrutinib (a newer medication) works for chronic hives (CSU) when prescribed in routine clinical practice in Germany. Remibrutinib is used when standard allergy medications don't work well enough. The study tracks your symptoms and treatment over 24 months to understand how well it helps real patients.
DürenAges 18 years+ - NCT07021495Recruiting
Skin disease study to improve treatment choices
This study looks at different skin diseases to find markers that can help guide treatment. It tests new treatments for several conditions like eczema, psoriasis, and lupus, with the goal of personalizing care.
Nijmegen, GelderlandAges 18 years+ - NCT07328178Recruiting
Understanding IgE proteins in allergies and immune conditions
This study looks at IgE, a protein involved in allergic reactions, to better understand its role in different immune-related diseases. It aims to find out how different forms of IgE relate to health and disease, which may help improve diagnosis or treatment.
Leuven, Vlaams-BrabantAges 18 years+ - NCT07358364Recruiting
Remibrutinib in real-world chronic hives
This study follows people with chronic hives (CSU) who start taking remibrutinib as part of their normal care. It looks at how well the medicine works in real life over 24 months.
Kirksville, MissouriAges 18 years+
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Chronic Spontaneous Urticaria trials by city
Studies with a site in or near these metro areas.
Chronic Spontaneous Urticaria trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for chronic spontaneous urticaria?
- Yes. Clin2 currently lists 26 recruiting chronic spontaneous urticaria studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic spontaneous urticaria trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic spontaneous urticaria trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.